By Donna Loyle, communications specialist, LIMR
Researchers are comparing comprehensive radiotherapy (radiation to the breast, chest wall and lymph nodes) to standard breast radiation in treating patients with early-stage breast cancer.
Study #NSABP B-51/RTOG 1304 is a randomized phase III trial of patients diagnosed with T1-3, N1 cancer. Patients whose primary tumor has been deemed HER2-positive or HER-2 negative are also eligible. Patients must have already undergone at least eight weeks of standard chemotherapy.
All patients in the study receive systemic therapy as planned. They also are grouped into two study arms, each with two groups:
- Arm1/Group 1A: Lumpectomy patients undergo whole breast RT once daily for five days for five weeks, followed by an RT boost to the lumpectomy cavity once daily five days for 1.5 weeks.
- Arm1/Group 2A: Mastectomy patients do not undergo RT.
- Arm 2/Group 2A: Lumpectomy patients undergo regional nodal RT with whole breast RT five days for five weeks, followed by an RT boost to the lumpectomy cavity five days for 1.5 weeks.
- Arm 2/Group 2B: Mastectomy patients undergo regional nodal RT five days for five weeks.
This study is approved for Lankenau Medical Center and Bryn Mawr Hospital. The principal investigators are Albert DeNittis, MD, and Paul Gilman, MD. For more, email firstname.lastname@example.org or visit www.mainlinehealth.org/research/clinical-trials/nsabp-b51-rtog-1304.